A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 701–800 of 999
Rapidly Progressive Glomerulonephritis
Bagga, A., & Menon, S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04883-5.50027-1 · Cited by 9
Principales vascularites nécrosantes systémiques
Guillevin, L., & Pagnoux, C. (2006) · EMC - Appareil locomoteur · doi:10.1016/s0246-0521(06)40613-6 · Cited by 9
Connective Tissue Diseases and the Heart
Arnett, F. C., & Willerson, J. T. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_112 · Cited by 9
Wegener’s granulomatosis: Is biologic therapy useful?
Sarraf, P., Kay, J., Friday, R. P., & Reginato, A. M. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0014-6 · Cited by 9
“Similarly, in a large randomized trial of cyclophosphamide induction followed by maintenance therapy with azathioprine or daily oral cyclophosphamide alone, Jayne et al. [ 33 ] achieved a disease-free survival of 84.5% by 18 months after study entry with the combination regimen, which was comparable to that of 86.3% u…”
ResultInfluentialGranulomatosis with Polyangiitis (Wegener's)
Hoffman, G. S., Langford, C. A., & Specks, U. (2012) · doi:10.1002/9781118355244.ch22 · Cited by 9
Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Ikle, D., & Stone, J. H. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1311108 · Cited by 9
Comment traiter une vascularite nécrosante ?
Guillevin, L. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.06.008 · Cited by 8
BILATERAL RETINAL BRANCH VASCULAR OCCLUSION—A FIRST PRESENTATION OF CROHN DISEASE
Abdul-Rahman, A. M., & Raj, R. (2010) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e318196bd79 · Cited by 8
Dhaun, N., Saunders, A. J., Bellamy, C. O. C., Gallardo, R., Manson, L. M., & Kluth, D. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0796-7 · Cited by 8
“As with other studies [20, 28], we found distinct clinical phenotypes depending on the type of ANCA present.”
BackgroundResultPharmacological approaches to CNS vasculitis: where are we at now?
Pagnoux, C., & Hajj‐Ali, R. A. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1112265 · Cited by 8
Besada, E. (2016) · Autoimmune Diseases · doi:10.1155/2016/8095695 · Cited by 8
“The current standard of care of AAV that includes remission induction with high dose of glucocorticoids and cyclophosphamide [2], followed by lower dose of glucocorticoids with either azathioprine or methotrexate for remission maintenance [3, 4], is challenged by rituximab (RTX).”
BackgroundTreating vasculitis with conventional immunosuppressive agents
Jayne, D. R. W. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79.s3.10 · Cited by 8
Self-citationChen, Y., Gao, E., Yang, L., Liu, X., Li, K., Liu, Z., Zeng, C., Zhang, H., Liu, Z., & Hu, W. (2016) · Rheumatology International · doi:10.1007/s00296-016-3492-5 · Cited by 8
Forbess, L. J., Griffin, K. W., & Spiera, R. (2014) · PubMed · Cited by 8
Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist’s perspective
Haris, A., Dolgos, S., & Polner, K. (2016) · International Urology and Nephrology · doi:10.1007/s11255-016-1419-4 · Cited by 8
“Relapse rates were 16 and 14 % in the AZA and CYC arms, respectively [60].”
BackgroundHow to treat ANCA‑associated vasculitis: practical messages from 2016 EULAR/ERA‑EDTA recommendations
Sznajd, J., & Mukhtyar, C. B. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3598 · Cited by 8
Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Cabral, D. A., & Morishita, K. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00036-3 · Cited by 10
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 9
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
Egan, A. C., Kronbichler, A., Neumann, I., Bettiol, A., Carlson, N., Cid, M. C., Emmi, G., Gopaluni, S., Harper, L., Hauser, T., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.05.018 · Cited by 8
Self-citationA glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
Moura, M. C., Branco, C., Martins-Martinho, J., Ferraro, J. L., Berti, A., Nogueira, E., & Ponte, C. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221125979 · Cited by 10
Current modalities in the diagnosis of pulmonary vasculitis
Casian, A., & Jayne, D. R. W. (2012) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.697895 · Cited by 8
Self-citationTherapeutic plasma exchange and renal related vasculitis: Therapeutic apheresis academy 2010
Balogun, R. A., & Abdel‐Rahman, E. M. (2011) · Journal of Clinical Apheresis · doi:10.1002/jca.20306 · Cited by 8
“For long-term maintenance therapy, azathioprine may be a reasonable alternative to cyclophosphamide [27].”
BackgroundTers, M. E., Muthyala, U., Philipneri, M., Hussein, F. A., & Lentine, K. L. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.14479 · Cited by 8
VASCULITIS AND THE INTENSIVE CARE
Tervaert, J. W. C. (2007) · Acta Clinica Belgica · doi:10.1179/acb.2007.094 · Cited by 8
Self-citationDiffuse Alveolar Hemorrhage and Rare Infiltrative Disorders of the Lung
Collard, H. R., King, T. E., & Schwarz, M. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00060-2 · Cited by 8
Anti-neutrophil Cytoplasmic Antibody–Associated Vasculitis
Chung, S. A., & Monach, P. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00089-9 · Cited by 12
Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy
Schneider, C. A., Wunderlich, G., Bleistein, J., Fink, G. R., Deckert, M., Brunn, A., & Lehmann, H. C. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315878 · Cited by 8
Gapud, E. J., Manno, R., Seo, P., Hanouneh, M. A., & Geetha, D. (2018) · Cureus · doi:10.7759/cureus.2372 · Cited by 8
Tanemoto, M., Hisahara, S., Hirose, B., Ikeda, K., Matsushita, T., Suzuki, S.-I., Manabe, T., Imai, T., & Shimohama, S. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3866-19 · Cited by 8
“The medical history and examination findings did not suggest primary vasculitis such as anti-neutrophilic cytoplasmic antibody-associated vasculitis (AAV), sarcoidosis, cryoglobulinemia, infections, or drug-induced neuropathies.”
BackgroundLimited Utility of Rapamycin in Severe, Refractory Wegener’s Granulomatosis
Koening, C. L., Hernández‐Rodríguez, J., Molloy, E. S., Clark, T. M., & Hoffman, G. S. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080664 · Cited by 8
How can relapses be detected and prevented in primary systemic small-vessel vasculitides?
Langford, C. A. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.11.003 · Cited by 8
New-generation therapy for ANCA-associated vasculitis
Jayne, D. R. W. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0855-z · Cited by 8
“Cyclophosphamide exposure has been reduced by restricting its use to the induction phase and by intravenous pulsed dosing [4].”
BackgroundSelf-citationLeflunomide versus methotrexate in Wegener's granulomatosis
Jayne, D. R. W. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem050 · Cited by 8
Self-citationAnti-neutrophil cytoplasm antibody associated vasculitis
Hewins, P., & Savage, C. O. S. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00094-8 · Cited by 8
TWEAK: a novel biomarker for lupus nephritis?
Dhaun, N., & Kluth, D. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2846 · Cited by 8
“Current immunosuppressive therapy for LN is often associated with significant side effects [3], and, despite treatment, some patients develop progressive renal injury resulting in end-stage renal disease.”
BackgroundAdvances in therapeutic treatment options for ANCA-associated vasculitis
Carpenter, S., Tervaert, J. W. C., & Yacyshyn, E. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1760837 · Cited by 8
Self-citationTreatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Berti, A., Cornec, D., & Dua, A. B. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.03.004 · Cited by 9
Antineutrophil cytoplasmic antibody-associated vasculitis
Konda, R., Rajasekaran, A., & Rizk, D. V. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001004 · Cited by 10
Biologic agents in the treatment of granulomatosis with polyangiitis
Specks, U. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79.s3.11 · Cited by 7
Atualização do tratamento das vasculites associadas a anticorpo anticitoplasma de neutrófilos
Santana, A. N. C., Woronik, V., Halpern, A. S. R., & Barbas, C. S. V. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000600016 · Cited by 7
ANCA Associated Glomerulonephritis- An In-Depth Review
Warraich, A. K. I. (2014) · Journal of Nephrology & Therapeutics · doi:10.4172/2161-0959.1000147 · Cited by 7
“On the other hand, remission induction is now achievable in almost 90% patients by six months [67] with survival rates are around 75% [68].”
BackgroundNishioka, K., Yamaguchi, S., Yasuda, I., Yoshimoto, N., Kojima, D., Kaneko, K., Aso, M., Nagasaka, T., Yoshida, E., Uchiyama, K., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.874831 · Cited by 7
“Remission was maintained in the patient with prednisolone (10 mg/day) and azathioprine (2 mg/kg/day) until 2020 (15).”
BackgroundRituximab como terapia de mantenimiento en las vasculitis asociadas a ANCA: ¿cómo, cuándo y por qué?
Alba, M. A., & Flores-Suárez, L. F. (2015) · Reumatología Clínica · doi:10.1016/j.reuma.2015.06.002 · Cited by 7
“regularmente: 6 (2-11) g 12% en tratados de forma”
BackgroundWegener-Granulomatose und mikroskopische Polyangiitis
de Groot, K., & Reinhold‐Keller, E. (2009) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-008-0425-z · Cited by 7
Tarzi, R. M., & Harper, L. (2014) · Medicine · doi:10.1016/j.mpmed.2013.12.010 · Cited by 7
What matters for patients with vasculitis?
Novakovich, E., & Grayson, P. C. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.01.016 · Cited by 7
Updates in the Diagnosis and Treatment of Vasculitis
Sakkas, L. I., & Katsiari, C. G. (2013) · InTech eBooks · doi:10.5772/46068 · Cited by 8
Uto, K., Yanagi, S., Tsubouchi, H., Matsumoto, N., & Nakazato, M. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.09.016 · Cited by 7
Quinn, K. A., Monti, S. M., Christensen, R., Jayne, D. R. W., Langford, C. A., Lanier, G. E., Mahr, A., Pagnoux, C., Shea, B., Tugwell, P., et al. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.07.001 · Cited by 7
Self-citationGadó, K., Szabó, L. Z., Csákó, L., & Domján, G. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29666 · Cited by 7
The spectrum of granulomatous vasculitides
Pagnoux, C., Bienvenu, B., & Guillevin, L. (2006) · Future Rheumatology · doi:10.2217/17460816.1.6.729 · Cited by 7
“Once remission is achieved [197], induction therapy must be switched to maintenance therapy with a less toxic immunosuppressant, such as azathioprine, methotrexate or mycophenolate mofetil, for at least 12 additional months (total treatment duration should be ≥18 months).”
BackgroundAntineutrophil cytoplasmic antibody–associated vasculitis
Unizony, S. H., & Stone, J. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00157-1 · Cited by 10
Henriksson, M. M., Weiner, M., Sperker, W., Berlin, G., Segelmark, M., Martinez, A. J., Audzijoniene, J., Griškevičius, A., Newman, E., Blaha, M., et al. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103227 · Cited by 7
“The maintenance therapy was more in line with azathioprine, mycophenolate, methotrexate than prolonged cyclophosphamide [6,29 – 31].”
BackgroundGlomerular, Vascular, and Tubulo-Interstitial Diseases
Assadi, F. K. (2007) · Springer eBooks · doi:10.1007/978-0-387-74602-9_8 · Cited by 7
Diagnosis and Treatment of Chronic Immune-mediated Neuropathies
Latov, N., Gorson, K. C., Brannagan, T. H., Freeman, R. L., Apostolski, S., Berger, A. R., Bradley, W. G., Briani, C., Bril, V., Busis, N. A., et al. (2006) · Journal of Clinical Neuromuscular Disease · doi:10.1097/01.cnd.0000205575.26451.e4 · Cited by 7
Rituximab and leflunomide for Wegener’s granulomatosis: a long-term follow-up
Henes, J., Kanz, L., & Koetter, I. (2010) · Rheumatology International · doi:10.1007/s00296-010-1462-x · Cited by 7
“However, data from cyclophosphamide studies suggest that a maintenance treatment after cyclophosphamide induction may reduce the rate of relapses [ 4 , 5]. As the patient cohorts in the studies on rituximab for ANCA associated vasculitis are very heterogeneous and small, a definite conclusion for the necessity of a ma…”
BackgroundMaintaining remission in a patient with vasculitis
Floßmann, O., & Jayne, D. R. W. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0863 · Cited by 7
Self-citationTime to focus on outcome assessment tools for childhood vasculitis
Demirkaya, E., Luqmani, R. A., Ayaz, N. A., Karaoğlu, A., & Özen, S. (2011) · Pediatric Rheumatology · doi:10.1186/1546-0096-9-29 · Cited by 8
“DEI was used in three RCTs and several open-label studies [53-56].”
MethodTreatment of ANCA-Associated Vasculitides
Guillevin, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-40136-2_35 · Cited by 7
Therapeutic Interventions for Systemic Vasculitis
Hoffman, G. S. (2010) · JAMA · doi:10.1001/jama.2010.1676 · Cited by 7
Antineutrophil cytoplasmic antibodies: are they pathogenic?
Specks, U. (2004) · PubMed · Cited by 7
Alberici, F., Floßmann, O., Lamprecht, P., Loudon, K. W., Padoan, R., Popov, T., Salvarani, C., & Mohammad, A. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1655326 · Cited by 11
Afectación pulmonar de las vasculitis
Martín-Suñé, N., & Blanco, J. J. R. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2012.04.007 · Cited by 6
New developments in treatments for systemic vasculitis
Goglin, S. E., & Chung, S. A. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102270 · Cited by 7
Treatment of antineutrophil cytoplasmic antibody-associated vasculitis
Rich, E. N., & Brown, K. K. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32835701d6 · Cited by 6
Indications actuelles de l’azathioprine en néphrologie
Ladrière, M. (2012) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2012.08.002 · Cited by 6
Which maintenance therapy for ANCA vasculitis?
Nachman, P. H. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.52 · Cited by 6
Quality of life and outcome measures in vasculitis
Tómasson, G. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2013.01.003 · Cited by 6
Treatment of ANCA-Associated Vasculitis, Where to Go?
Kallenberg, C. G. M. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8325-z · Cited by 6
Todoerti, M., Pipitone, N., Matucci‐Cerinic, M., Montecucco, C., & Caporali, R. F. (2011) · PubMed · Cited by 6
Rapidly Progressive Glomerulonephritis
Butani, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-97220-6_6 · Cited by 6
Ford, J. A., & Monach, P. A. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30077-3 · Cited by 6
Early Renal Recovery after the First Flare of Pauci-Immune Glomerulonephritis
Zaworski, J., Gnemmi, V., Bataille, P., HACHULLA, E., Glowacki, F., Gibier, J., Daroux, M., Ratsimbazafy, A., Bitton, L., Humez, S., et al. (2022) · American Journal of Nephrology · doi:10.1159/000520285 · Cited by 7
Johnsen, A. K., & Weinblatt, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00056-5 · Cited by 7
Granulomatosis with Polyangiitis
Pagnoux, C., & Villa‐Forte, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_8 · Cited by 6
ANCA-Associated Renal Vasculitis - An Update
Tesař, V., & Hrušková, Z. (2013) · Contributions to nephrology · doi:10.1159/000348634 · Cited by 6
File, I., Pucsok, K., Trinn, C., Újhelyi, L., Balla, J., & Mátyus, J. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29735 · Cited by 6
Complete resolution of refractory cutaneous arteritis by intravenous cyclophosphamide pulse therapy
Kawakami, T., Okano, T., Takeuchi, S., Kimura, S., & Soma, Y. (2015) · International Journal of Dermatology · doi:10.1111/ijd.12863 · Cited by 6
Vasculitis Integrated Clinical Assessment Database
Wilson, A. S., BACON, P. A., Young, S. P., & Carruthers, D. M. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181c6813f · Cited by 6
“This has lead to their adoption for major collaborative clinical trials performed by the European Vasculitis Study group.(18) The scoring of BVAS and VDI is a time-consuming process.”
MethodSelf-citationWang, Q., Mou, S., Xu, W., Qi, C., & Ni, Z. (2012) · Renal Failure · doi:10.3109/0886022x.2012.736069 · Cited by 6
“The treatment protocols have been described previously.(11,12) The induction therapy included corticosteroids in combination with cyclophosphamide (CTX).”
MethodTuin, J., Sanders, J., van Beek, A. P., Hoek, A., & Stegeman, C. A. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39522 · Cited by 6
“Our results therefore show that the introduction of induction therapy followed by sequential therapy, due to among others the Cyclophosphamide versus Azathioprine During Remission of Systemic Vasculitis (CYCAZAREM) study, led to an important improvement in the treatment of AAV by lowering cyclophosphamide exposure and…”
Pagnoux, C., & Mendel, A. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1656527 · Cited by 6
Evidence-based treatment of ANCA-associated vasculitis with kidney involvement
Bulanov, N. M., Kozlovskaya, N. L., Tao, E., Novikov, P., & Moiseev, S. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-4-72-84 · Cited by 7
Cutaneous granulomatous vasculitis and extravascular granulomas
Pagnoux, C., Kluger, N., Francès, C., & Guillevin, L. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.2.315 · Cited by 6
von Vietinghoff, S., Choi, M., Rolle, S., Luft, F. C., & Kettritz, R. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22832 · Cited by 6
Pusey, C. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030192 · Cited by 6
“(22) reported that switching from cyclophosphamide to azathioprine at 3 mo, for maintenance treatment in generalized disease, re-”
BackgroundSelf-citationUnderstanding the Role of Rituximab in ANCA GN
Pendergraft, W. F., & Falk, R. J. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014100997 · Cited by 6
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.30 · Cited by 6
Pulmonale Manifestationen von Vaskulitiden
Hellmich, B., Henes, J., & Hetzel, J. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_9 · Cited by 5
Morishita, M., Watanabe, H., Yan, M., Zeggar, S., Hiramatsu, S., Ohashi, K., Miyawaki, Y., Katsuyama, E., Katsuyama, T., Narazaki, M., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.8287 · Cited by 5
“1646 totoxicity and digestive intolerance (5-8).”
ResultCurrent and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis
Berti, A., Specks, U., Keogh, K. A., & Cornec, D. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0073-z · Cited by 6
Hellmich, B. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-0632-9 · Cited by 5
Rapidly Progressive Glomerulonephritis
Menon, S., & Bagga, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_20 · Cited by 5
Ashok, A., Russell, L. E., Dey, M., & Kouranloo, K. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i4.15094 · Cited by 5
“Through trials such as the CYCAZAREM, there is evidence to suggest that cyclophosphamide combined with glucocorticoids for 3-6 months can induce remission in 90% of patients (28,29).”
Landman, A., Levine, M., & León-Benedetti, A. D. (2024) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00782-x · Cited by 5
“It has a similar efficacy to CYC in remission maintenance [31].”
Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Joshi, L., Hamour, S., Salama, A. D., Pusey, C. D., Lightman, S., & Taylor, S. R. J. (2009) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152809787582552 · Cited by 5
Self-citationLinking classification and therapeutic management of vasculitides
Baldwin, C., Carette, S., & Pagnoux, C. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0654-x · Cited by 5
“For more severe disease (that is, with renal, life- and/or organ-threatening manifestations), high-dose glucocorticoids must be combined with a more potent drug, such as cyclophosphamide, or rituximab for GPA or MPA [79–81].”
BackgroundRituximab en el tratamiento de las vasculitis asociadas a ANCA: ¿el futuro hoy?
Alba, M. A., & Flores-Suárez, L. F. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.10.006 · Cited by 5
Wegener’s granulomatosis: an update on diagnosis and therapy
Manna, R., Cadoni, G., Ferri, E., Verrecchia, E., Giovinale, M., Fonnesu, C., Calò, L., Armato, E., & Paludetti, G. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.4.481 · Cited by 5
Hasegawa, M., & Sato, S. (2010) · Springer eBooks · doi:10.1007/978-3-540-78814-0_37 · Cited by 5
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.